Literature DB >> 21084241

[Epithelial mesenchymal transition during development in fibrosis and in the progression of carcinoma].

J-P Thiery1, K Chua, Wen Jing Sim, R Huang.   

Abstract

Epithelial mesenchymal transition (EMT) is a fundamental mechanism controlling multiple events during embryonic development. Mesenchymal cells appear transiently in some diploblasts, the most primitive species characterized by two epithelial layers. Since almost 800 million years, EMT has been conserved throughout evolution to control morphogenetic events, such as the formation of the three primary germ layers during gastrulation. Most interestingly, specific molecular pathways have been conserved in many different species to drive EMT. In the animal kingdom, a recurrent theme is that EMT controls the intercellular adhesion machinery and the dynamics of its associated cytoskeleton. EMT pathways are also tightly connected to determination and differentiation programs, and are reactivated in adult tissues following injury or exposure to toxic agents. EMT is now shown to operate during the early stages of carcinoma invasion leading to blood or lymph vessel intravasation of malignant cells. The converse mechanism - mesenchymal-epithelial transition (MET) - then operates at distant sites from the primary tumor to form macrometastases from isolated micrometastatic cells. The mesenchymal-like state of carcinoma confers stemness, protection from cell death, escape from immune response and, most importantly, resistance to conventional and targeted therapies. Our laboratory has designed an EMT high-throughput screen of small molecular weight compounds and biologics in order to establish new therapeutic approaches that interfere with the plasticity of carcinoma cells. New therapeutic interventions are envisioned to delay tumor recurrence.

Entities:  

Mesh:

Year:  2010        PMID: 21084241     DOI: 10.1684/bdc.2010.1206

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  16 in total

1.  Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.

Authors:  Woo Jung Sung; Ki-Sung Park; Sang Gyu Kwak; Dae-Sung Hyun; Jae Seok Jang; Kwan-Kyu Park
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 2.  Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases.

Authors:  Hong Zhao; Yanting Dong; Xinrui Tian; Thian Kui Tan; Zhuola Liu; Ye Zhao; Yun Zhang; David Ch Harris; Guoping Zheng
Journal:  World J Nephrol       Date:  2013-08-06

3.  Placenta growth factor promotes migration through regulating epithelial-mesenchymal transition-related protein expression in cervical cancer.

Authors:  Wei Huang; Shuli Zhu; Qiang Liu; Chanyu Li; Li Li
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 4.  Twist in hepatocellular carcinoma: pathophysiology and therapeutics.

Authors:  Hui Zou; Xing Feng; Jian-Guo Cao
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

Review 5.  Epigenetic control of epithelial-mesenchymal-transition in human cancer.

Authors:  Tobias Kiesslich; Martin Pichler; Daniel Neureiter
Journal:  Mol Clin Oncol       Date:  2012-09-25

6.  CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.

Authors:  Jiyeon Kim; Seong Hwan Kim
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

7.  Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line.

Authors:  Giuseppe Pirozzi; Virginia Tirino; Rosa Camerlingo; Renato Franco; Aantonello La Rocca; Eleonora Liguori; Nicola Martucci; Francesca Paino; Nicola Normanno; Gaetano Rocco
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

8.  Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition.

Authors:  Chiao-Yin Sun; Shih-Chung Chang; Mai-Szu Wu
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

9.  The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae.

Authors:  Sandra Michaela Frei; Colette Hemsley; Theresa Pesch; Silvia Lang; Achim Weber; Ekkehard Jehle; Anne Rühl; Michael Fried; Gerhard Rogler; Michael Scharl
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

10.  Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.

Authors:  Kian Ngiap Chua; Li Ren Kong; Wen Jing Sim; Hsien Chun Ng; Weijie Richard Ong; Jean Paul Thiery; Hung Huynh; Boon Cher Goh
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.